India is largely protected from the newly imposed United States tariffs on patented drugs because of its strength in exporting generic medicines, according to the Global Trade Research Initiative (GTRI). The country primarily exports affordable generic medicines to America, which are currently exempt from these tariffs.
While the direct impact is expected to be minimal, Indian firms that produce specialized drugs or inputs for patented medicines may encounter some pressure. The GTRI suggests that future uncertainty remains if the tariffs are extended to include generic drugs.
The current tariff structure primarily targets patented pharmaceuticals, leaving India’s generic exports largely untouched. This provides a buffer for the Indian pharmaceutical industry, which plays a significant role in supplying cost-effective medicines to the US market. However, the situation could evolve if trade policies change.
About the Author
